These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 32462910)

  • 1. How biomarkers can improve pneumonia diagnosis and prognosis: procalcitonin and mid-regional-pro-adrenomedullin.
    Spoto S; Legramante JM; Minieri M; Fogolari M; Terrinoni A; Valeriani E; Sebastiano C; Bernardini S; Ciccozzi M; Angeletti PS
    Biomark Med; 2020 May; 14(7):549-562. PubMed ID: 32462910
    [No Abstract]   [Full Text] [Related]  

  • 2. Diagnostic and prognostic value of procalcitonin and mid-regional pro-adrenomedullin in septic paediatric patients.
    Solé-Ribalta A; Bobillo-Pérez S; Valls A; Girona-Alarcón M; Launes C; Cambra FJ; Jordan I; Esteban E
    Eur J Pediatr; 2020 Jul; 179(7):1089-1096. PubMed ID: 31974673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic and prognostic role of procalcitonin (PCT) and MR-pro-Adrenomedullin (MR-proADM) in bacterial infections.
    Angeletti S; Spoto S; Fogolari M; Cortigiani M; Fioravanti M; De Florio L; Curcio B; Cavalieri D; Costantino S; Dicuonzo G
    APMIS; 2015 Sep; 123(9):740-8. PubMed ID: 26058482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thirty and ninety days mortality predictive value of admission and in-hospital procalcitonin and mid-regional pro-adrenomedullin testing in patients with dyspnea. Results from the VERyfing DYspnea trial.
    Travaglino F; Russo V; De Berardinis B; Numeroso F; Catania P; Cervellin G; Nigra SG; Geraci F; Bressan MA; Guerrini S; Cavazza M; Folli C; Monzani V; Battista S; Mengozzi G; Noto P; Carpinteri G; Semplicini A; Stella F; Ingrassia S; Moscatelli P; Giuntini P; Salerno G; Cardelli P; Di Somma S
    Am J Emerg Med; 2014 Apr; 32(4):334-41. PubMed ID: 24559907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of Procalcitonin (PCT) and Mid regional pro-Adrenomedullin (MR-proADM) in risk stratification of critically ill febrile patients in Emergency Department (ED). A comparison with APACHE II score.
    Travaglino F; De Berardinis B; Magrini L; Bongiovanni C; Candelli M; Silveri NG; Legramante J; Galante A; Salerno G; Cardelli P; Di Somma S
    BMC Infect Dis; 2012 Aug; 12():184. PubMed ID: 22874067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proadrenomedullin, a useful tool for risk stratification in high Pneumonia Severity Index score community acquired pneumonia.
    Courtais C; Kuster N; Dupuy AM; Folschveiller M; Jreige R; Bargnoux AS; Guiot J; Lefebvre S; Cristol JP; Sebbane M
    Am J Emerg Med; 2013 Jan; 31(1):215-21. PubMed ID: 23000327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Procalcitonin and MR-Proadrenomedullin Combination with SOFA and qSOFA Scores for Sepsis Diagnosis and Prognosis: A Diagnostic Algorithm.
    Spoto S; Cella E; de Cesaris M; Locorriere L; Mazzaroppi S; Nobile E; Lanotte AM; Pedicino L; Fogolari M; Costantino S; Dicuonzo G; Ciccozzi M; Angeletti S
    Shock; 2018 Jul; 50(1):44-52. PubMed ID: 29023361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of mid-regional pro-adrenomedullin (MR-proADM) in patients with community-acquired pneumonia: a systematic review and meta-analysis.
    Liu D; Xie L; Zhao H; Liu X; Cao J
    BMC Infect Dis; 2016 May; 16():232. PubMed ID: 27230573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Procalcitonin and MR-proAdrenomedullin combination in the etiological diagnosis and prognosis of sepsis and septic shock.
    Spoto S; Fogolari M; De Florio L; Minieri M; Vicino G; Legramante J; Lia MS; Terrinoni A; Caputo D; Costantino S; Bernardini S; Ciccozzi M; Angeletti S
    Microb Pathog; 2019 Dec; 137():103763. PubMed ID: 31574301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of mid-regional pro-adrenomedullin (MR-proADM) as prognostic marker in COVID-19 critically ill patients: An observational prospective study.
    Montrucchio G; Sales G; Rumbolo F; Palmesino F; Fanelli V; Urbino R; Filippini C; Mengozzi G; Brazzi L
    PLoS One; 2021; 16(2):e0246771. PubMed ID: 33556140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mid regional pro-adrenomedullin for the prediction of organ failure in infection. Results from a single centre study.
    Viaggi B; Poole D; Tujjar O; Marchiani S; Ognibene A; Finazzi S
    PLoS One; 2018; 13(8):e0201491. PubMed ID: 30102716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MR-proANP, MR-proADM, and PCT in Patients Presenting with Acute Dyspnea in a Medical Emergency Unit.
    Heining L; Giesa C; Ewig S
    Lung; 2016 Apr; 194(2):185-91. PubMed ID: 26748496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397].
    Christ-Crain M; Morgenthaler NG; Stolz D; Müller C; Bingisser R; Harbarth S; Tamm M; Struck J; Bergmann A; Müller B
    Crit Care; 2006; 10(3):R96. PubMed ID: 16805922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diagnostic and prognostic power of biomarkers to improve the management of community acquired pneumonia in the emergency department].
    Julián-Jiménez A; Timón Zapata J; Laserna Mendieta EJ; Sicilia-Bravo I; Palomo-de Los Reyes MJ; Cabezas-Martínez A; Laín-Terés N; Estebaran-Martín J; Lozano-Ancín A; Cuena-Boy R
    Enferm Infecc Microbiol Clin; 2014 Apr; 32(4):225-35. PubMed ID: 24182623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of mid-regional pro-atrial natriuretic peptide, procalcitonin, and mid-regional pro-adrenomedullin for the diagnosis and risk stratification of dyspneic ED patients.
    Cinar O; Cevik E; Acar A; Kaya C; Ardic S; Comert B; Yokusoglu M; Bilgi C; Meisner M; Madsen T
    Am J Emerg Med; 2012 Nov; 30(9):1915-20. PubMed ID: 22742951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Midregional proadrenomedullin as a prognostic tool in community-acquired pneumonia.
    Huang DT; Angus DC; Kellum JA; Pugh NA; Weissfeld LA; Struck J; Delude RL; Rosengart MR; Yealy DM
    Chest; 2009 Sep; 136(3):823-831. PubMed ID: 19363212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of midregional pro-adrenomedullin as a marker of organ damage and predictor of mortality in patients with sepsis.
    Bernal-Morell E; García-Villalba E; Vera MDC; Medina B; Martinez M; Callejo V; Valero S; Cinesi C; Piñera P; Alcaraz A; Marin I; Muñoz A; Cano A
    J Infect; 2018 Mar; 76(3):249-257. PubMed ID: 29246637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of pro-adrenomedullin for identifying adverse outcomes in community-acquired pneumonia.
    España PP; Capelastegui A; Mar C; Bilbao A; Quintana JM; Diez R; Esteban C; Bereciartua E; Unanue U; Uranga A
    J Infect; 2015 May; 70(5):457-66. PubMed ID: 25499199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers and clinical scores to identify patient populations at risk of delayed antibiotic administration or intensive care admission.
    Gonzalez Del Castillo J; Wilson DC; Clemente-Callejo C; Román F; Bardés-Robles I; Jiménez I; Orviz E; Dastis-Arias M; Espinosa B; Tornero-Romero F; Giol-Amich J; González V; Llopis-Roca F;
    Crit Care; 2019 Oct; 23(1):335. PubMed ID: 31665092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MR- proADM to detect specific types of organ failure in infection.
    Andrés C; Andaluz-Ojeda D; Cicuendez R; Nogales L; Martín S; Martin-Fernandez M; Almansa R; Calvo D; Esteban-Velasco MC; Vaquero-Roncero LM; Ríos-Llorente A; Sanchez-Barrado E; Muñoz-Bellvís L; Aldecoa C; Bermejo-Martin JF
    Eur J Clin Invest; 2020 Jun; 50(6):e13246. PubMed ID: 32307701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.